All In Biotech

Drug Trial Radar · NCT04028492

Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis

VP-VLY-686-3301: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Iii Study To Assess The Efficacy Of Tradipitant In Relieving Symptoms Of Gastroparesis

Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 979 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

979

Actual

Start

Aug 20, 2019

Primary completion

Feb 21, 2025

Study completion Feb 21, 2025

Sponsor

Lead sponsor
Vanda PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jul 22, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To investigate the safety and efficacy of tradipitant versus placebo in relieving nausea and other symptoms of gastroparesis.

Conditions

  • Idiopathic Gastroparesis
  • Diabetic Gastroparesis
  • Gastroparesis

Interventions

  • TradipitantDrug

    BID

  • PlaceboDrug

    BID

  • Open Label TradipitantDrug

    BID

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Week 12 in the Biweekly Average of Daily Nausea Severity Score Using MMRM Model ITT PopulationTime frame: 12 weeks

Locations

36 sites in 1 country. Site status is shown where the registry gives one.

  • Vanda Investigational Site

    Birmingham, Alabama

  • Vanda Investigational Site

    Peoria, Arizona

  • Vanda Investigational Site

    Little Rock, Arkansas

  • Vanda Investigational Site

    Chula Vista, California

  • Vanda Investigational Site

    La Jolla, California

  • Vanda Investigational Site

    Los Angeles, California

  • Vanda Investigational Site

    Los Angeles, California

  • Vanda Investigational Site

    Maitland, Florida

  • Vanda Investigational Site

    Palmetto Bay, Florida

  • Vanda Investigational Site

    Tampa, Florida

  • Vanda Investigational Site

    Morrow, Georgia

  • Vanda Investigational Site

    Wauconda, Illinois

  • Vanda Investigational Site

    West Des Moines, Iowa

  • Vanda Investigational Site

    Wichita, Kansas

  • Vanda Investigational Site

    Louisville, Kentucky

  • Vanda Investigational Site

    Marrero, Louisiana

  • Vanda Investigational Site

    Chevy Chase, Maryland

  • Vanda Investigational Site

    Boston, Massachusetts

  • Vanda Investigational Site

    Boston, Massachusetts

  • Vanda Investigational Site

    Chesterfield, Missouri

  • Vanda Investigational Site

    Las Vegas, Nevada

  • Vanda Investigational Site

    Brooklyn, New York

  • Vanda Investigational Site

    Charlotte, North Carolina

  • Vanda Investigational Site

    Raleigh, North Carolina

  • Vanda Investigational Site

    Columbus, Ohio

  • Vanda Investigational Site

    Huber Heights, Ohio

  • Vanda Investigational Site

    Edmond, Oklahoma

  • Vanda Investigational Site

    Tulsa, Oklahoma

  • Vanda Investigational Site

    Philadelphia, Pennsylvania

  • Vanda Investigational Site

    Chattanooga, Tennessee

  • Vanda Investigational Site

    Nashville, Tennessee

  • Vanda Investigational Site

    Houston, Texas

  • Vanda Investigational Site

    Houston, Texas

  • Vanda Investigational Site

    Plano, Texas

  • Vanda Investigational Site

    San Antonio, Texas

  • Vanda Investigational Site

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.